KRAS and neoplasm: With a second sample (PR04-1) of particularly low-tumor purity as revealed by pathology review (Fig. 3d) and bulk sequencing (Fig. 3e), Tapestri data identified 40 out of 3866 nuclei (1%) of this sample carrying at least one of KRAS p.G12V, TP53 p.R186H, or SMAD4 p.508D (Fig. 3f, g).